https://www.selleckchem.com/products/Temsirolimus.html Hepatitis C virus (HCV) affects 71 million people worldwide. The development of reliable diagnostic tools in the last 2 decades and recent implementation of highly potent and safe antiviral drug combinations have paved the way to potential elimination of HCV as a public health threat by 2030. This article briefly discusses current and upcoming solutions for simplification of HCV testing taking into account the most recent guidance documents issued by major professional societies. The general consensus is that all patients with suspected HCV infection should be tested for anti-HCV antibodies as a first-line diagnostic test. Some anti-HCV rapid diagnostic tests have already attained the performance of standard anti-HCV enzyme immunoassays. If anti-HCV antibodies are detected, the presence of HCV RNA or HCV core antigen should be determined to identify patients with ongoing infection. Several innovative devices for detecting HCV in serum or plasma are in the late stages of development and are based on loop-mediantries. In at least two countries, Georgia and Egypt, a macro-elimination approach has shown impressive real-life results relatively quickly. Erythema induratum of Bazin (EIB) is a rare tuberculid form characterized by hypersensitivity to Mycobacterium tuberculosis antigens. There are a few case series related to EIB in the literature. We evaluated the demographic, clinical, treatment, and follow-up characteristics of patients diagnosed with EIB. Demographic, clinical, histopathologic, and imaging findings as well as treatment and follow-up properties were evaluated in 22 patients retrospectively diagnosed with EIB between January 2013 and December 2018. Of the 22 patients,90.9% were female and 9.1% were male. The mean age was 57.2 ± 12.9 years. Ten of the patients had a history of contact with tuberculosis, and one had a history of active pulmonary tuberculosis. The purified protein derivate (PPD) test aver